Literature DB >> 19496807

Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Cynthia L Harden1, Jennifer Hopp, Tricia Y Ting, Page B Pennell, Jacqueline A French, W Allen Hauser, Samuel Wiebe, Gary S Gronseth, David Thurman, Kimford J Meador, Barbara S Koppel, Peter W Kaplan, Julian N Robinson, Barry Gidal, Collin A Hovinga, Andrew N Wilner, Blanca Vazquez, Lewis Holmes, Allan Krumholz, Richard Finnell, Claire Le Guen.   

Abstract

A committee assembled by the American Academy of Neurology (AAN) reassessed the evidence related to the care of women with epilepsy (WWE) during pregnancy, including the risk of pregnancy complications or other medical problems during pregnancy, change in seizure frequency, the risk of status epilepticus, and the rate of remaining seizure-free during pregnancy. The committee evaluated the available evidence according to a structured literature review and classification of relevant articles. For WWE who are taking antiepileptic drugs (AEDs), there is probably no substantially increased risk (>2 times expected) of cesarean delivery or late pregnancy bleeding, and probably no moderately increased risk (>1.5 times expected) of premature contractions or premature labor and delivery. There is possibly a substantially increased risk of premature contractions and premature labor and delivery during pregnancy for WWE who smoke. WWE should be counseled that seizure freedom for at least 9 months prior to pregnancy is probably associated with a high likelihood (84-92%) of remaining seizure-free during pregnancy. WWE who smoke should be counseled that they possibly have a substantially increased risk of premature contractions and premature labor and delivery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496807     DOI: 10.1111/j.1528-1167.2009.02128.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

Review 1.  Update on anticonvulsant drugs.

Authors:  Derek J Chong; Carl W Bazil
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

2.  [Family planning in women with epilepsy].

Authors:  S Weil; G Luef
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

3.  Child development following in utero exposure: levetiracetam vs sodium valproate.

Authors:  R Shallcross; R L Bromley; B Irwin; L J Bonnett; J Morrow; G A Baker
Journal:  Neurology       Date:  2011-01-25       Impact factor: 9.910

Review 4.  Neural tube defects, folate, and immune modulation.

Authors:  Kerina J Denny; Angela Jeanes; Kristin Fathe; Richard H Finnell; Stephen M Taylor; Trent M Woodruff
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-09

Review 5.  [New developments in epileptogenesis and therapeutic perspectives].

Authors:  H Lerche; A Vezzani; H Beck; I Blümcke; Y Weber; C Elger
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

6.  Advances in epilepsy: new perspectives on new-onset epilepsy, comorbidities, and pharmacotherapy.

Authors:  Andres M Kanner
Journal:  F1000 Med Rep       Date:  2010-07-14

Review 7.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 8.  Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts.

Authors:  Page B Pennell
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

9.  Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.

Authors:  T L Reisinger; M Newman; D W Loring; P B Pennell; K J Meador
Journal:  Epilepsy Behav       Date:  2013-08-02       Impact factor: 2.937

Review 10.  Pharmacokinetics of drugs in pregnancy.

Authors:  Maisa Feghali; Raman Venkataramanan; Steve Caritis
Journal:  Semin Perinatol       Date:  2015-11       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.